Smoot K, Marginean H, Gervasi-Follmar T, Chen C, et al. Evaluating the efficacy and safety of transitioning patients with multiple sclerosis from natalizumab to ocrelizumab (OCTAVE). Mult Scler 2023 Jun 15:13524585231175284. doi: 10.1177/13524585231175284.
PMID: 37317841